publication date: May. 3, 2019

NCI Trials NCI Trials for May

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10204

A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

University of Texas MD Anderson Cancer Center LAO

Tawbi, Hussein Abdul-Hassan

(713) 792-4185

 

Phase I – 10249

MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Lonial, Sagar

(404) 778-3921

 

Phase I – ADVL1712

A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924, IND# 142772) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome.

Pediatric Early Phase Clinical Trial Network

Tarlock, Katherine G.

(206) 667-7121

 

Phase I/II – 10216

A Phase I/II Study of AZD9291(Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center LAO

Owen, Dwight Hall

(614) 685-2039

Continue reading NCI Trials for May 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.